James Kearns, MD
As treatment strategies evolve across all tumor types, investigators are putting a more prominent focus on improving quality of life (QoL) for patients with cancer, in addition to prolonging their survival. This consideration should inform the role of surgery in prostate cancer, said James Kearns, MD.
For example, in patients with high-risk disease, it is important to consider the need for additional therapies down the road, he explained. Therefore, when deciding whether to use surgery in this population, physician needs to be sure that the adverse events (AEs) associated with the procedure can be effectively managed.
“Overall, we need to be doing a better job of deciding which patients will benefit from surgery,” said Kearns, an assistant professor of Urology at Levine Cancer Institute. “Just because we are capable of taking out the prostate does not necessarily mean we should.”
... to read the full story